Reducing fatigue, depression, and cognitive deficits with modafinil in low-grade glioma patients.

N/A

1. Modafinil influences fatigue, cognitive functioning, and quality of life of LGG patients;

2. There is a correlation between (changes in) fatigue, cognition, and quality of life on the one hand, and functional connectivity in the brains of LGG patients on the other.

1. Baseline, before treatment;

2. After first 6 weeks of treatment;

3. After second 6 weeks of treatment.

Patients will be randomized into two groups. These groups will first receive six weeks of treatment (with either placebo or modafinil), followed by a wash-out period of one week. Hereafter, another treatment period of six weeks will take place, in which patient groups will receive placebo or modafinil respectively (opposite of first treatment). Treatment will begin with 100 mg modafinil, or matching placebo, upon waking and at lunch (200 mg/day). After one week, the dose will be doubled (400 mg/day). If patients experience adverse events at the higher dose, they will be allowed to decrease the medication to the previous dose. Patients will continue at either 200 mg/day or 400 mg/day until the second visit, six weeks after the initial visit.